Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumothorax-II01:27

Pneumothorax-II

1.5K
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
1.5K
Pneumothorax-I01:26

Pneumothorax-I

2.1K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
2.1K
Endoscopic Studies II: Thoracocentesis01:26

Endoscopic Studies II: Thoracocentesis

2.3K
Thoracentesis(Thoracocentesis), commonly known as pleural tap, is a medical procedure where a 22 gauge needle is inserted into the pleural space, the area between the lung and chest wall. This procedure is commonly performed to diagnose or treat various respiratory disorders.
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
2.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

667
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
667
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

1.1K
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Diphtheria01:28

Diphtheria

141
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

A Distinct Approach for Molecular ABO Typing: A Case of Serology-Genotype Discrepancy Within a Family.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026
Same journal

Foreign Body Reaction Mimicking Relapse in Primary Mediastinal B-Cell Lymphoma: A Diagnostic Pitfall.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026
Same journal

A Rare Case of POEMS-Associated Multicentric Castleman Disease with an Atypical Osteolytic Presentation.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026
Same journal

Rothmund-Thomson Syndrome Type 2 Misdiagnosed as Dyskeratosis Congenita.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026
Same journal

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms (MPN) and Pruritus.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026
Same journal

Recurrent Pseudo-Hemolysis as a Diagnostic Pitfall in Cobalamin E Deficiency: A Seven-Year Delayed Diagnosis.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026

Related Experiment Video

Updated: Apr 15, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

652

Dasatinib-related chylothorax.

Yen Min Huang1, Cheng Hsu Wang, Jen Seng Huang

  • 1Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-Oncology, Keelung, Taiwan.

Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
|March 26, 2015
PubMed
Summary
This summary is machine-generated.

Dasatinib, a leukemia drug, can rarely cause chylothorax, a buildup of fluid in the chest. This report details a case and reviews literature to understand this rare dasatinib side effect.

More Related Videos

Author Spotlight: Optimized Protocol for Detecting Antigen-Specific T Cells in Mouse Lungs Using Tetramers
09:15

Author Spotlight: Optimized Protocol for Detecting Antigen-Specific T Cells in Mouse Lungs Using Tetramers

Published on: July 19, 2024

1.9K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

652
Author Spotlight: Optimized Protocol for Detecting Antigen-Specific T Cells in Mouse Lungs Using Tetramers
09:15

Author Spotlight: Optimized Protocol for Detecting Antigen-Specific T Cells in Mouse Lungs Using Tetramers

Published on: July 19, 2024

1.9K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Pulmonology

Background:

  • Dasatinib is a tyrosine kinase inhibitor used for chronic myeloid leukemia.
  • Fluid retention, such as pleural effusion, is a common dasatinib side effect.
  • Dasatinib-induced chylothorax is a rare but serious adverse event.

Purpose of the Study:

  • To report a rare case of chylothorax in a patient treated with dasatinib.
  • To review the existing literature on dasatinib-related chylothorax.
  • To hypothesize the underlying mechanism of this adverse event.

Main Methods:

  • Case report of a 40-year-old female patient.
  • Literature review of dasatinib-induced chylothorax.
  • Analysis of clinical presentation, pathophysiology, and management.

Main Results:

  • The patient developed chylothorax after initiating dasatinib therapy.
  • Literature review revealed limited data on dasatinib-related chylothorax.
  • The study proposes a potential mechanism for dasatinib-induced chylothorax.

Conclusions:

  • Chylothorax is a rare but significant adverse event associated with dasatinib.
  • Further research is needed to elucidate the pathophysiology and optimize management.
  • Early recognition and intervention are crucial for patients experiencing this side effect.